Why Are Investors Backing This Biotech Without VC Funding?

Just 9 Days Left, Invest Before the Raise Closes August 27th at $3.00/Share. 

Here’s something surprising: Thousands of investors are choosing Cytonics over traditional VC-funded biotechs.

And it’s not just because they love the science (they do). It’s because of the structure, the mission, and the opportunity.

Now, with only 9 days left before the current round closes, this is your final chance to join them at the $3.00/share valuation.

Future raises may come, but they won’t look like this one.


Why No VC = A Feature, Not a Bug

Traditional biotech looks like this:

• VC firms control the board
• The Founder and company insiders get boxed out and lose control
• Early investors get buried under VC liquidation preferences
• Retail investors? Usually, nowhere near the deal

Cytonics flipped the model:

• $25M+ raised without a dime of VC funding
• 7,000+ “everyday” shareholders (and growing)
• Same terms for everyone, including you

No strings, no special deals, and no insiders cashing out first.


Why So Many Are Backing Cytonics Now

Because they’re doing what Big Pharma hasn’t:

• CYT-108 completed a Phase 1 human trial with zero drug-related adverse events
• Developed a first-in-class biologic based on a naturally occurring human protein (A2M)
• Secured 25 international patents
• Positioned to enter Phase 2, the most value-driving stage in biotech
• Built without dilution from VC firms or private equity

This isn’t hype, this is biotech with proof and purpose.


Only 9 Days Left to Invest at $3.00/Share

Here’s what’s on the line:

• Own shares in a clinical-stage company on the verge of Phase 2
• Get in at $3.00/share before valuation increases
• Be part of a grassroots movement that’s rewriting how biotech is funded
• Join over 7,000 investors who already said “screw Big Pharma”

This Raise Closes August 27th at 11:59 PM

Join a new model for biotech before the window shuts.